Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
Alain AmstutzFrédérique ChammartinAnnette AudigéAnna L EichenbergerDominique L BraunPatrizia AmicoMarcel P StoeckleBarbara HasseMatthaios Papadimitriou-OlivgerisOriol ManuelCédric BongardMacé M SchuurmansRené HageDominik DammMichael TammNicolas J MuellerAndri RauchHuldrych F GunthardMichael T KollerChristof M SchönenbergerAlexandra GriessbachNiklaus D LabhardtRoger D KouyosAlexandra TrkolaKatharina KusejkoHeiner C BucherIrene A AbelaMatthias BrielBenjamin Speichnull nullnull nullPublished in: The Journal of infectious diseases (2024)
Bivalent mRNA vaccination elicited a robust humoral response in individuals with HIV or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare.